Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
43.32
+1.62 (3.88%)
Nov 10, 2026, 4:08 PM HKT

HKG:2315 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
371.52173.233.54-382.95-601.95-545.58
Depreciation & Amortization
156.26156.26164.7179.3174.1128.1
Other Amortization
4.24.24.493.15--
Loss (Gain) From Sale of Assets
-0.79-0.79-0.01-1.830.08-0.39
Loss (Gain) From Sale of Investments
-2.21-2.210.36-0.15-44.7-2.13
Loss (Gain) on Equity Investments
22.3122.3129.7510.0314.770.4
Stock-Based Compensation
35.2435.2422.6430.9815.3127.75
Provision & Write-off of Bad Debts
12.0712.079.44.281.423.12
Other Operating Activities
-20.4618.7977.7889.842.0433.13
Change in Accounts Receivable
-82.22-82.22-96.68-39.02-4.59-35.86
Change in Inventory
-13.18-13.18-12.933.79-6.4-29.96
Change in Accounts Payable
12.212.2-47.3511.947.3519.04
Change in Unearned Revenue
-0.8-0.830.89.98-8.0716.75
Change in Income Taxes
-----0.8-
Change in Other Net Operating Assets
35.1735.17-5.244.168.1719.86
Operating Cash Flow
529.33370.25211.25-76.65-303.27-365.78
Operating Cash Flow Growth
41.60%75.27%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-371.65-87.82-37.13-126.62-240.27-198.67
Sale of Property, Plant & Equipment
-0.080.291.1126.341.644.76
Divestitures
-----6.86-
Investment in Securities
-164.34-97.33-101.09-91.76109.78
Investing Cash Flow
-564.77-184.86-137.12-100.28-153.74-84.13

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-248.27239.33319.91209.6-
Long-Term Debt Repaid
--289.95-207.38-172.98-68.77-57.13
Lease Payments
-27.38-27.38-22.37-22.16-21.57-14.98
Net Debt Issued (Repaid)
-161.11-41.6831.94146.93140.83-57.13
Issuance of Common Stock
1,1691,169--521.06311.04
Repurchase of Common Stock
-18.07-18.07-9.51-8.2-18.99-
Other Financing Activities
-444.5-129.19-114.46-176.55-55.69-34.47
Financing Cash Flow
545.11979.86-92.03-37.82587.2219.44

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-15.692.842.753.4714.24-0.38
Net Cash Flow
493.981,168-15.15-211.28144.44-230.85

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
157.68282.43174.12-203.26-543.54-564.45
Free Cash Flow Growth
-47.49%62.21%----
Free Cash Flow Margin
8.57%20.48%17.76%-28.35%-101.81%-159.20%
Free Cash Flow Per Share
0.360.710.44-0.51-1.43-1.56
Levered Free Cash Flow
-126.09484.049.32-231.5-423.55-397.16
Unlevered Free Cash Flow
-86.71528.4266.62-169.1-388.46-372.52
Free Cash Flow After Leases
130.3255.06151.75-225.42-565.11-579.42

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
31.0231.0231.2824.08177.66
Cash Income Tax Paid
30.6216.99.320.64--
Change in Working Capital
-48.82-48.82-131.39-9.2495.65-10.18